Almorexant
As of the edition of 20 October 2026, Almorexant is a small molecule: went quiet in 2014; acts on HCRTR1 and HCRTR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2014
- Kind
- Small molecule
- Registered trials
- 6, 0 stopped early
- Disease areas
- Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B and 2 company-target rows on route A because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Almorexant.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product2 company-target rows are on route A because of Almorexant.
See the 2 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Midnight Pharma | Lead sponsor of trials | 2006 to now |
| Idorsia Pharmaceuticals | Lead sponsor of trials | 2011 to now |